{
    "nct_id": "NCT06710379",
    "official_title": "A Phase 1a/b Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors",
    "inclusion_criteria": "* Phase 1a Dose Escalation: Subjects with histologically confirmed select advanced solid tumors, including metastatic castration resistant prostate cancer (mCRPC), gastric cancer (GC), and non-small cell lung cancer (NSCLC).\n* Phase 1b Dose Expansion: Subjects with histologically confirmed prostate adenocarcinoma that is confirmed to be castration resistant (i.e., serum testosterone < 50 ng/dL [< 2.0 nM]) and that is intolerant/resistant to standard of care (SOC) therapies.\n* Measurable disease according to RECIST version 1.1 or evaluable disease per PCWG3 for subjects with prostate cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 in 1a; 0-2 in 1b\n* Adequate hematologic, liver, and renal function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active and uncontrolled central nervous system metastases\n* Significant cardiovascular disease\n* History of another malignancy other than the one for which the subject is being treated on this study within 3 years\n* Receipt of any anticancer or investigational therapy within: 5 elimination half-lives or 14 days (whichever is less); 4 weeks for any therapeutic radiopharmaceutical for prostate cancer\n* History of (non-infectious) ILD/pneumonitis that required steroids within 2 years of study enrollment, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Receiving systemic antimicrobial treatment for active infection; routine antimicrobial prophylaxis is permitted",
    "miscellaneous_criteria": ""
}